

2012-07-05

FANCI/BACH1 Acetylation at Lysine 1249 Regulates the DNA Damage Response

Jenny X. Xie
University of Massachusetts Medical School

Et al.

Let us know how access to this document benefits you.

Follow this and additional works at: <https://escholarship.umassmed.edu/oapubs>



Part of the Biochemistry, Biophysics, and Structural Biology Commons, Cancer Biology Commons, Genetics and Genomics Commons, and the Medicine and Health Sciences Commons

Repository Citation

Xie JX, Peng M, Guillemette S, Quan S, Maniatis S, Wu Y, Venkatesh A, Shaffer SA, Brosh RM, Cantor SB. (2012). FANCI/BACH1 Acetylation at Lysine 1249 Regulates the DNA Damage Response. Open Access Publications by UMass Chan Authors. <https://doi.org/10.1371/journal.pgen.1002786>. Retrieved from <https://escholarship.umassmed.edu/oapubs/2332>

This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in Open Access Publications by UMass Chan Authors by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.

FANCI/BACH1 Acetylation at Lysine 1249 Regulates the DNA Damage Response

Jenny Xie¹, Min Peng¹, Shawna Guillemette¹, Steven Quan¹, Stephanie Maniatis², Yuliang Wu³, Aditya Venkatesh¹, Scott A. Shaffer², Robert M. Brosh Jr.³, Sharon B. Cantor^{1*}

1 Department of Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America, **2** Proteomics and Mass Spectrometry Facility and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America, **3** Laboratory of Molecular Gerontology, National Institute on Aging, NIH Biomedical Research Center, National Institutes of Health, Baltimore, Maryland, United States of America

Abstract

BRCA1 promotes DNA repair through interactions with multiple proteins, including CtIP and FANCI (also known as BRIP1/BACH1). While CtIP facilitates DNA end resection when de-acetylated, the function of FANCI in repair processing is less well defined. Here, we report that FANCI is also acetylated. Preventing FANCI acetylation at lysine 1249 does not interfere with the ability of cells to survive DNA interstrand crosslinks (ICLs). However, resistance is achieved with reduced reliance on recombination. Mechanistically, FANCI acetylation facilitates DNA end processing required for repair and checkpoint signaling. This conclusion was based on the finding that FANCI and its acetylation were required for robust RPA foci formation, RPA phosphorylation, and Rad51 foci formation in response to camptothecin (CPT). Furthermore, both preventing and mimicking FANCI acetylation at lysine 1249 disrupts FANCI function in checkpoint maintenance. Thus, we propose that the dynamic regulation of FANCI acetylation is critical for robust DNA damage response, recombination-based processing, and ultimately checkpoint maintenance.

Citation: Xie J, Peng M, Guillemette S, Quan S, Maniatis S, et al. (2012) FANCI/BACH1 Acetylation at Lysine 1249 Regulates the DNA Damage Response. *PLoS Genet* 8(7): e1002786. doi:10.1371/journal.pgen.1002786

Editor: Sharon E. Plon, Baylor College of Medicine, United States of America

Received: October 13, 2011; **Accepted:** May 10, 2012; **Published:** July 5, 2012

Copyright: © 2012 Cantor et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was funded by RO1 grant CA129514-01A1 and by charitable gifts from the Vitone family. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: Sharon.Cantor@umassmed.edu

Introduction

The hereditary breast cancer associated gene product, BRCA1 is an essential tumor suppressor. To promote genomic stability, BRCA1 interacts with multiple protein partners. In particular, through its C-terminal BRCT repeats, BRCA1 directly interacts with Abraxas, CtIP and FANCI (also known as BRIP1 or BACH1 (BRCA1-associated C-terminal helicase 1)). These BRCT-interacting proteins contribute to the function of BRCA1 in the DNA damage response (DDR). Abraxas serves to localize BRCA1 to sites of DNA damage and CtIP promotes the initiation of DNA end resection, which is critical for HR [1–3]. FANCI also participates in localizing BRCA1 to sites of DNA damage, in DNA repair, and in checkpoint signaling; however, its distinct function is less clear.

Elucidating how FANCI functions in the DDR is important, as mutations in the *FANCI* gene are associated with hereditary breast cancer as well as with the rare cancer prone syndrome Fanconi anemia (FA) within the FANCI patient complementation group (FA-J) [4]. As a DEAH-family helicase, it is expected that FANCI metabolizes DNA substrates to facilitate DNA repair. Consistent with this idea, recombinant-FANCI is a 5'-3' helicase and translocase that can unwind D-loops and displace RAD51 [5]. In cells, FANCI also localizes to sites of DNA damage. Furthermore, when FANCI is absent, catalytically inactive, or lacks BRCA1 binding, cells display defects in double strand break

repair (DSBR) and HR [6–9]. Recently, FANCI was identified as a factor essential for maintaining the DNA damage induced checkpoint in response to ionizing radiation [10]. Despite these findings, FANCI-deficient cells are only mildly sensitive to agents that induce DSBs [11].

To explain these findings, it has been proposed that FANCI functions in DSBR, but has a more significant role in processing replication forks stalled at lesions, such as DNA interstrand crosslinks (ICLs). In support of this idea, FANCI-null cells, similar to other FA patient cells, are extremely sensitive to agents that induce ICLs, such as cisplatin, melphalan, or mitomycin C (MMC) [7], [12], [13]. This sensitivity is reversed by complementation of FA-J cells with wild-type FANCI (FANCI^{WT}), but not with catalytically inactive FANCI mutants [6], [8], [14]. Interestingly, the mechanism by which FANCI mediates ICL processing is regulated by BRCA1 binding. HR is favored when BRCA1 binds FANCI. When BRCA1 binding is prevented, lesion bypass is favored by a mechanism requiring the translesion synthesis polymerase pol η [9]. Thus, complementation of FA-J cells with a BRCA1-interaction defective mutant FANCI^{S990A} reverses ICL sensitivity but does not fully restore FANCI function.

Here, we present evidence that FANCI contributes to lesion processing by promoting a robust DDR. Essential for this function is FANCI acetylation on a specific lysine residue. As such, preventing FANCI acetylation suppresses DNA end resection that normally serves to engage recombination-based processing. Thus,

Author Summary

The BRCA1–Fanconi anemia (FA) pathway is required for both tumor suppression and cell survival, particularly following treatment with DNA damaging agents that induce DNA interstrand crosslinks (ICLs). ICL processing by the BRCA–FA pathway includes promotion of homologous recombination (HR) and DNA damage tolerance through translesion synthesis. However, little is known about how the BRCA–FA pathway or these ICL processing mechanisms are regulated. Here, we identify acetylation as a DNA damage–dependent regulator of the BRCA–FA protein, FANCI. FANCI acetylation at lysine 1249 is enhanced by expression of the histone acetyltransferase CBP and reduced by expression of histone deacetylases HDAC3 or SIRT1. Furthermore, acetylation on endogenous FANCI is induced upon treatment of cells with agents that generate DNA lesions. Consistent with this post-translation event regulating FANCI function during cellular DNA repair, preventing FANCI acetylation skews ICL processing. Cells have reduced reliance on HR factor Rad54 and greater reliance on translesion synthesis polymerase pol η . Our data indicate that FANCI acetylation contributes to DNA end processing that is required for HR. Furthermore, resection-dependent checkpoint maintenance relies on the dynamic regulation of FANCI acetylation. The implication of these findings is that FANCI acetylation contributes to DNA repair choice within the BRCA–FA pathway.

both BRCT-interacting proteins, CtIP and FANCI undergo DNA damage induced changes in acetylation that further regulates their function in the DDR to promote genomic stability.

Results

FANCI is acetylated by CBP and deacetylated by HDAC3 or SIRT1

As observed for CtIP, FANCI binds directly to the BRCT domains of BRCA1 [6], [9], [15]. Given that CtIP function is inactivated by acetylation [16], we addressed whether FANCI was similarly modified. For this analysis, myc-tagged FANCI was co-transfected with various Flag- or HA-tagged histone acetyltransferases. In an immunoblot probed with a pan-acetyl lysine antibody, we found that the precipitated FANCI was acetylated only when CBP was over-expressed (Figure 1A). Moreover, FANCI acetylation was induced by CBP in a dose dependent manner (Figure 1B).

FANCI acetylation was preserved most effectively by the inclusion of two types of deacetylase inhibitors, trichostatin-A (TSA) and nicotinamide (NAM) (Figure 1C). Thus, we considered that more than one class of histone deacetylase (HDAC) could deacetylate FANCI. TSA inactivates class I and class II HDACs, whereas NAM inactivates the nicotinamide adenosine dinucleotide (NAD⁺)-dependent sirtuin (class III) family of HDACs (including SIRT1 to SIRT7) [17]. FANCI acetylation was reduced more when either Flag-tagged-HDAC3 or SIRT1 were overexpressed in 293T cells than observed upon overexpression of HDAC1, HDAC2, or SIRT6 (Figure 1D). Titration of the SIRT1 expression vector transfected into 293T cells revealed that 0.01 μ g of the SIRT1 construct matched the expression level of 4 μ g of the HDAC3 construct. At this similar level of expression, HDAC3 more efficiently deacetylated FANCI than did SIRT1 (Figure 1E). Together, these data implicate that FANCI can be acetylated by CBP and deacetylated by HDAC3 as well as SIRT1 when over-expressed.

FANCI is acetylated at lysine residue 1249

To identify the FANCI acetylation site(s), myc-tagged C-terminal FANCI truncation mutants were co-transfected with CBP into 293T cells. By Immunoblot analysis using the pan-acetyl antibody, we found that acetylation of FANCI required amino acids 1239 to 1249 (Figure 2A, 2C). Consistent with this region being modified, a C-terminal domain of FANCI similar to a C-terminal p53 control was acetylated *in vitro* by a HAT-domain protein (Figure 2B, 2C). To determine, which of three lysine (K) residues in this C-terminal region were required for acetylation, we generated three independent FANCI mutant constructs that converted lysines 1240, 1242, or 1249 to arginine (R). Further transfection experiments revealed that the K1249 was the dominant site for FANCI acetylation, a lysine that is not conserved in chicken or *C. elegans* FANCI species (Figure 2D, 2E).

Next, we sought to provide more conclusive evidence that CBP-induced acetylation on FANCI was at the K1249 site. We purified FANCI from 293T cells transfected with a C-terminal myc-tagged FANCI^{WT} or the FANCI^{K1249R} mutant species by immunoprecipitation using a myc antibody. Isolated proteins were then digested with trypsin and subjected to tandem mass spectrometry analysis (LC-MS/MS). FANCI-derived peptides covering the entire sequence were analyzed, and acetylation sites were identified using MASCOT search algorithm. Most of the acetylated lysine residues were detected in overlapping peptides derived from at least two independent protein preparations. In the FANCI^{WT}, one of these sites was K1249 (Figure 2F). Interestingly, even though by antibody detection, the FANCI^{K1249R} mutant scores unmodified as in Figure 2D; FANCI^{WT} and FANCI^{K1249R} mutant had three additional acetylation marks detected by mass spectrometry (Figure S1). Furthermore, the K1249R mutant had five additional acetylated lysines not found in wild-type FANCI, suggesting that these sites are not available when K1249 is acetylated (Figure S1). Thus, immunoblot and mass spectrometry analysis confirm that the very last amino acid of FANCI, lysine 1249 is acetylated.

FANCI acetylation is enhanced by certain forms of DNA damage

Given that DNA damage reduces CtIP acetylation [16], we addressed whether DNA damage could alter FANCI acetylation. Endogenous FANCI acetylation was enhanced in MCF7 cells treated with zeocin, camptothecin (CPT), or hydroxyurea (HU) as compared to ultraviolet radiation (UV), MMC, or methyl methanesulfonate (MMS) at the dose and time-post treatment analyzed (Figure 3A). Notably, zeocin had a more robust induction of FANCI acetylation despite the dose of zeocin, CPT, or UV having similar affect on cell survival (Figure S2; data not shown). As found previously, DNA damage did not measurably alter FANCI co-precipitation with BRCA1 with the exception of UV damage, which could reflect the UV-induced BRCA1 degradation [11], [18] (Figure 3A). DNA damage also induced FANCI acetylation in HeLa cells, in response to not only CPT, but also MMC (Figure 3A). In response to DNA damage, we also noted that FANCI protein levels were sometimes enhanced (Figure 3A). To clarify whether acetylation or our ability to detect acetylation was induced by DNA damage, we sought to induce DNA damage in cells in which our ability to detect FANCI acetylation was not limiting. Indeed, the amount of acetylation on similar levels of exogenous FANCI^{WT} achieved with low dose CBP expression was considerably enhanced following treatment with zeocin or CPT (Figure 3B, 3C). Interactions with BRCA1 and MLH1 were not required for the CBP-induced acetylation of FANCI, because BRCA1- and MLH1-interaction-defective mutants, FANCI^{S990A}




Figure 1. CBP promotes, and HDAC3 and SIRT1 reduce, FANCI acetylation. A. CBP expression promotes FANCI acetylation. Myc-tagged FANCI was co-transfected with HA- or FLAG-tagged acetyltransferase (CBP, p300, PCAF, Tip60, or MOF) into 293T cells. As detected by immunoblot of whole cell extracts (WCE), acetyltransferases were expressed (upper panel), however only CBP promoted FANCI acetylation as shown by FANCI immunoprecipitation (lower panel). B. FANCI acetylation is induced by CBP in a dose dependent manner. Myc-tagged FANCI was co-transfected with increasing amounts of CBP and lysates were used for immunoblot with the indicated antibodies. C. FANCI deacetylation was prevented by both TSA and NAM. 293T cells co-expressing Myc-tagged FANCI and CBP were exposed to TSA, NAM, TSA+NAM, or neither and lysates were used for immunoblot with the indicated antibodies. D. FANCI was deacetylated by both HDAC3 and SIRT1. Myc-tagged FANCI was co-transfected with CBP and Flag-tagged deacetylase (HDAC1, HDAC2, HDAC3, SIRT1, or SIRT6) into 293T cells and lysates were immunoblotted with the indicated antibodies. E. When SIRT1 (0.01 μg) and HDAC3 (4 μg) were similarly expressed (upper panel), HDAC3 promoted more FANCI deacetylation (lower panel). Cell lysates were collected and analyzed for expression and/or acetylation following immunoprecipitation with the indicated antibodies. doi:10.1371/journal.pgen.1002786.g001

and FANCI^{K141/142A} were readily modified (data not shown). In contrast, following treatment with CPT, acetylation was not detected on the FANCI^{K1249R} mutant (Figure 3C), indicating that DNA damage-induced FANCI acetylation requires the C-terminal K1249 residue. It remains to be determined, however if FANCI acetylation is induced by a distinct type of DNA damage.

FANCI acetylation mutants are functional

The enhanced FANCI acetylation following DNA damage led us to hypothesize that this modification facilitated FANCI function in DNA repair. To address this possibility, we made use of this lysine to arginine FANCI^{K1249R} mutant that prevents acetylation and also generated a lysine to glutamine FANCI^{K1249Q} mutant to




Figure 2. FANCI is acetylated at lysine 1249. A. The C-terminus of FANCI is required for acetylation. Myc-tagged FANCI mutant constructs were co-expressed with CBP into 293T cells. Cell lysates were collected and analyzed for expression and/or acetylation following immunoprecipitation with the indicated antibodies. B. The FANCI C-terminus is acetylated *in vitro*. The recombinant histone acetyltransferase (HAT) domain of p300 was incubated with recombinant FANCI C-terminal (CT) or p53-CT in the presence of 3H-acetyl CoA. Reaction products were separated by SDS-PAGE and analyzed by autoradiography. Expression of recombinant proteins was determined by Coomassie staining. C. Schematic presentation of wild-type and truncation mutations of FANCI. D. Lysine 1249 is required for FANCI acetylation. The Myc-tagged FANCI mutant constructs noted were co-expressed with CBP into 293T cells and cell lysates were collected and analyzed for expression and/or acetylation following immunoprecipitation with the indicated antibodies. E. Sequence alignment of last 6 residues found in distinct FANCI species. F. Confirmation of the K1249 acetylation is shown by tandem mass spectrum of FANCI peptide (amino acid 1243–1249 with Myc tag). *Ions validating localization of acetylation site. doi:10.1371/journal.pgen.1002786.g002

structurally mimic acetylation. Consistent with these mutants being functional, the purified recombinant proteins displayed similar catalytic activities as FANCI^{WT} (Figure S3). In addition, they were expressed at similar levels as FANCI^{WT} in FANCI-null FA-J cells (Figure 4A). Similar to FANCI^{WT}, FANCI^{K1249R} and FANCI^{K1249Q} precipitated with known FANCI interacting partners, BRCA1 and MLH1 [6], [8] (Figure 4B). In addition, the mutants co-localized with BRCA1 in response to DNA damage and the FA-J cells expressing FANCI^{WT} or mutants had similar asynchronous cell cycle profiles (Figure 4C, 4D). The acetylation mutants also restored MMC resistance and the ability of FA-J cells to exit from an abnormal G2/M accumulation, albeit in a manner slightly more robust than FANCI^{WT} (Figure 4E, 4F). Together, these findings suggested that the mutants were enzyme active and functional *in vivo*; however the mechanism by which the

FANCI mutants restore ICL resistance could be distinct from FANCI^{WT}.

FANCI acetylation contributes to the mechanism of lesion processing

Previously, complementation of FA-J cells with a BRCA1-binding defective mutant, FANCI^{S990A} gave the semblance of FANCI^{WT} function. In particular, MMC resistance was restored [8]. However, in contrast to FANCI^{WT}, FANCI^{S990A} provides resistance to MMC by a mechanism dependent on the DNA damage tolerance pathway. Within this tolerance pathway, translesion synthesis polymerases can bypass DNA lesions such as unhooked ICLs and intra-strand crosslinks generated by UV, but not DSBs generated by zeocin. Evidence that FANCI^{S990A} skewed lesion processing towards DNA damage tolerance was




Figure 3. FANCI acetylation is induced after DNA damage. A. Endogenous FANCI is acetylated in response DNA damage. MCF7 and HeLa cells were left untreated (UT) or treated with zeocin (6.25 μ g/ml for 1 h), MMC (250 nM for 1 h), UV (30 J/m²), MMS (300 μ g/ml for 4 h), HU (1 mM for 24 h), or CPT (1 μ M for 1 h). Cell lysates were collected at distinct times post damage (zeocin 24 h, MMC 24 h or as indicated, UV 6 h, CPT 24 h, MMS 4 h, and HU 24 h) and analyzed for expression and/or acetylation following immunoprecipitation with the indicated antibodies. B. Exogenous FANCI is acetylated on lysine 1249 in response to DNA damage. Myc-tagged FANCI wild-type or mutant species and CBP were co-transfected into 293T cells and left untreated (UT) or treated with zeocin (12.5 μ g/ml for 1 h) or C. CPT (1 μ M for 1 h). Cells were processed at different time points post DNA damage and analyzed for expression and/or acetylation following immunoprecipitation with the indicated antibodies.
doi:10.1371/journal.pgen.1002786.g003




Figure 4. FANCI acetylation mutants are functional. A. The acetylation mutants are expressed in FA-J cells. FA-J cells were complemented with vector, FANCI^{WT}, FANCI^{K1249R}, or FANCI^{K1249Q}. The FA-J cell lines were collected and analyzed or B. lysates were immunoprecipitated with FANCI antibodies and immunoblot with the indicated antibodies. C. The acetylation mutants localize in nuclear foci of FA-J cells. The FA-J cell lines were seeded onto 6-well plates and incubated overnight. The cells were treated with 1 mM HU and 24 h later immunofluorescence was performed with the indicated antibodies. D. The FA-J cell lines have similar cell cycle profiles. The FA-J cell lines were collected and analyzed by FACS to determine the percentage of cells with 2N and 4N DNA content. E. Expression of acetylation mutants restores MMC resistance. The FA-J cell lines were seeded onto 6 well plates and incubated overnight. The cells were either left untreated or treated with increasing doses of MMC. Cells were counted 8 days later and percent survival was calculated. Data represent mean percent \pm s.d. of survival from three independent experiments. F. Expression of acetylation mutants restores G2/M checkpoint exit. The FA-J cell lines were untreated or treated with 0.25 μ g/ml melphalan, collected at the indicated times, and analyzed by FACS to determine the percentage of cells in G2/M. Data represent mean percent \pm s.d. of survival from three independent experiments.
doi:10.1371/journal.pgen.1002786.g004

based on several findings. First, the sensitivity to MMC in these cells was restored upon depletion of the essential tolerance factor, Rad18 or the translesion polymerase pol η , but not upon depletion of the HR protein, Rad54. Second, in comparison to FANCI^{WT}, cells expressing FANCI^{S990A} were hyper-resistant to UV, a phenotype that was reversed upon pol η -depletion. Third, in comparison to FANCI^{WT}, FANCI^{S990A}-expressing cells were sensitive to zeocin, indicating reduced DSB β [9]. Thus, we sought to determine whether similar to the BRCA1-binding mutant, the acetylation mutants also functioned differently from FANCI^{WT}. To test this idea, the FA-J cell lines were left untreated or treated with increasing doses of MMC, zeocin, or UV. In comparison to the other FA-J cell lines, the FA-J cell line expressing the acetylation mutant FANCI^{K1249R} was hyper-resistant to UV, but unable to restore normal levels of zeocin resistance. In contrast, the FA-J cell line expressing the acetylation mimic FANCI^{K1249Q} displayed greater resistance to zeocin

(Figure 5A; Figure S2). Thus, in response to UV and zeocin, cells expressing the acetylation mutants are distinct from each other as well as from cells expressing FANCI^{WT}.

To further validate these results, we targeted recombination or DNA damage tolerance pathways by using siRNA reagents to Rad54 or pol η . Significantly, depletion of Rad54 suppressed the zeocin resistance of the FA-J cell line expressing FANCI^{K1249R} (Figure 5A, 5C). Likewise, depletion of pol η suppressed the UV hyper-resistance of the FA-J cell line expressing FANCI^{K1249R} (Figure 5A, 5C). Furthermore, depletion of pol η , but not Rad54 reversed the MMC resistance of the FA-J cell line expressing FANCI^{K1249R} (Figure 5B). In contrast, depletion of Rad54, but not pol η reduced the MMC resistance of the FA-J cell line expressing FANCI^{K1249Q} (Figure 5B). Together, these results indicate that the acetylation of FANCI at lysine 1249 contributes to the mechanism of lesion processing; preventing acetylation favors DNA damage tolerance and constitutive acetylation favors recombination.




Figure 5. FANCI^{K1249R} or FANCI^{K1249Q} promotes pol η - or Rad54-dependent repair, respectively. A. FA-J cells expressing acetylation mutants have a distinct response and reliance on repair or tolerance factors for DNA damage survival. The FA-J cell lines were transfected with siRNA against Luc, Pol η , or Rad54. The cells were treated with indicated doses of zeocin, UV, or as in B, with MMC and the percent survival was calculated 8 days later. Data represent mean percent \pm s.d. of survival from three independent experiments. C. Cells were collected and analyzed for expression with the indicated antibodies. doi:10.1371/journal.pgen.1002786.g005

FANCI acetylation is required for a robust DDR

How could FANCI acetylation affect lesion processing? Because both CtIP and FANCI are acetylated and directly bind to the BRCA1-BRCT domain, we speculated that FANCI might similarly have a role in DNA end resection. In particular, the

affect of CtIP acetylation on DNA end resection was analyzed in response to CPT [16]. We found RPA foci formation at 1 h post-CPT was more robust (64% and 65%) in the FANCI^{WT} and FANCI^{K1249Q} FA-J cell lines as compared to vector and FANCI^{K1249R} FA-J cell lines that had 47% and 29%, respectively




Figure 6. FANCI and its acetylation at 1249 promote an RPA response. A. Deficiency in FANCI or its acetylation impairs the CPT-induced RPA focus formation. The FA-J cell lines were seeded onto 6-well plates, incubated overnight, left untreated or treated with CPT 1 h and immunofluorescence was performed with the indicated antibodies. The percent of cells with RPA foci was quantified and graphed. Data represent mean \pm s.d. from three independent experiments. B. FANCI and its acetylation promote RPA phosphorylation at 1 h post-CPT. The complemented FA-J cell lines were either left untreated or treated for 1 h with the indicated dose of CPT and analyzed 1 h post-treatment. Cell lysates were collected, lysed, and analyzed with the indicated antibodies. C. FANCI acetylation promotes RPA phosphorylation at times greater than 1 h post-CPT. Same as above but collected at the time points indicated. doi:10.1371/journal.pgen.1002786.g006

(Figure 6A). Thus, as measured by RPA foci formation, FANCI^{WT} and the acetylation mimic FANCI^{K1249Q} were more active in DNA end resection.

RPA loading onto ssDNA also leads to its subsequent phosphorylation on Ser4 and Ser8 [3]. We found that the FA-J cell lines had a similar phosphorylation of Chk2 and γ -H2AX following exposure to two different doses of CPT, indicating that FANCI or its ability to be acetylated is not required for DSB formation in response to CPT (Figure 6B). Likewise, at 1 h post-CPT treatment, Chk1 phosphorylation was detected (Figure 6B). In contrast, RPA phosphorylation was most robust in the CPT-treated FANCI^{WT} and FANCI^{K1249Q} FA-J cell lines (Figure 6B). In support of these findings, reduced RPA phosphorylation was also detected in CPT-treated FANCI-deficient U2OS cells generated by siRNA reagents (Figure S4). Furthermore, at 4–

24 h post CPT treatment, we noted diminished RPA phosphorylation in FANCI^{K1249R} as compared with FANCI^{WT} and FANCI^{K1249Q} FA-J cell lines (Figure 6C). At this time, RPA phosphorylation in the FANCI^{K1249R} FA-J cells was also reduced compared to vector FA-J cells that had gained considerable RPA phosphorylation as compared to 1 h post-CPT (Figure 6B, 6C). In the response to zeocin, which induces DSBs independent of replication, RPA phosphorylation was similar in FA-J cell lines with or without FANCI^{WT} (Figure S5). Together, these results suggest a role for FANCI and its acetylation in DNA end resection at stalled replication forks as induced by CPT.

To address whether the contribution of FANCI acetylation to DNA end resection was sufficient to enhance HR, we next analyzed Rad51 foci formation. In response to CPT, we found that Rad51 foci were the most robust in FA-J cells complemented

with FANCI^{WT} or the FANCI^{K1249Q} mutant. Instead, Rad51 foci in the FA-J cells with vector or FANCI^{K1249R} were more anemic (Figure 7A). Furthermore, a greater number of FANCI^{K1249Q} expressing FA-J cells were positive for Rad51 foci as quantitated between 2–16 h after CPT treatment (Figure 7A). In contrast, the γ -H2AX foci did not have a significant difference between the FA-J cells lines. Thus, a greater proportion of γ -H2AX co-staining Rad51 foci were detected in FANCI^{K1249Q} or FANCI^{WT}, as compared to vector or FANCI^{K1249R} expressing FA-J cells (Figure 7A merge). Together, these findings demonstrate that in response to CPT, FANCI and its acetylation at 1249 promote DNA end processing events that enhance RPA phosphorylation, and both RPA and Rad51 focal accumulation.

Given these findings and the recent identification that FANCI promotes checkpoint maintenance [10], we considered that FANCI acetylation could be essential for maintaining the checkpoint. Defects in checkpoint maintenance were evaluated by determining if CPT treated FA-J cells traversed prematurely to mitosis. FA-J cells lacking FANCI^{WT} entered mitosis by 24 h post-CPT as indicated by a positive histone H3 phosphorylation (Figure 7B). These results are consistent with FANCI acetylation supporting checkpoint maintenance. However, FA-J cells expressing FANCI^{K1249R} or FANCI^{K1249Q} also failed to maintain the checkpoint, showing H3 phosphorylation by 24 h (Figure 7B). Substantiating this finding, at time points greater than 4 h post-CPT treatment, both mutants had reduced Chk1 phosphorylation as compared to FA-J cells expressing FANCI^{WT} (Figure 7B). Collectively, these findings suggest that FANCI acetylation enhances the initial DDR to facilitate recombination-based repair and limit translesion synthesis. Checkpoint maintenance however, requires FANCI and its dynamic regulation by acetylation (Figure 7C).

Discussion

Here we identify acetylation as a DNA damage-dependent regulator of the BRCA-FA protein, FANCI. We show that acetylation at lysine 1249 is a critical regulator of FANCI function during cellular DNA repair. We analyzed the expression of two FANCI mutants that mimicked either the constitutive deacetylated FANCI^{K1249R} or acetylated FANCI^{K1249Q} protein isoforms. While the mutants functioned similar to FANCI^{WT} in several assays and restored MMC resistance and exit from an abnormal G2/M checkpoint response to FA-J cells, the mutants were distinct from FANCI^{WT} with respect to lesion processing. Notably, FA-J cells expressing the acetylation mutants differentially relied on repair and tolerance factors for resistance to DNA damaging agents. Our findings further demonstrate that FANCI has the ability to potentiate HR and DNA damage induced acetylation is important for this function.

Another BRCA1-BRCT interacting protein, CtIP is acetylated and functions in DNA end resection. Thus, we considered that recombination-based lesion processing by the FANCI acetylation mimic, FANCI^{K1249Q} resulted from a function for FANCI acetylation in DNA end resection. To test this idea, the FA-J cells were treated with CPT, which generates breaks in S-phase. Indeed, FA-J cells expressing the acetylation mutants were distinct in the initial response to CPT. Specifically, FA-J cells expressing the FANCI^{K1249Q}, but not FANCI^{K1249R}, promoted DNA end resection post-CPT exposure as measured by presentation of RPA foci or its phosphorylation at serine residues 4 and 8. Furthermore, FA-J cells expressing the FANCI^{K1249Q}, as compared to FANCI^{K1249R} had 2.5-fold more cells with CPT-induced Rad51 foci. This more robust DDR could reflect a role for FANCI

acetylation in loading RPA, as shown for FANCI in response to HU [19]. Our data do not implicate a global role for FANCI in DNA end resection given that FANCI-deficiency did not affect the amount of RPA phosphorylation following zeocin, an agent that induces DSBs independent of replication. However, FANCI is acetylated when cells are exposed to CPT or zeocin. Thus, DSB-induced FANCI acetylation that is not associated with stalled or broken replication forks may contribute to some other aspect of the DDR, such as checkpoint maintenance.

In fact, we find that FANCI as well as its acetylation are essential for checkpoint maintenance. Specifically, in the absence of FANCI or its DNA damage induced acetylation, Chk1 phosphorylation was induced, but not maintained and correspondingly cells underwent a more rapid transit into mitosis post-CPT. Interestingly, we found that similar to FA-J cells expressing the acetylation mutant FANCI^{K1249R}, FA-J cells expressing the acetylation mimic FANCI^{K1249Q} failed to maintain the checkpoint despite an initial DDR to CPT. Thus, some other aspect of checkpoint signaling is perturbed in FA-J cells that express the acetylation mimic. Perhaps this mutant fails to mediate a protein interaction or act upon a DNA substrate important for checkpoint maintenance. Instead FANCI acetylation could serve as a switch, in which acetylation and de-acetylation is essential to maintain the checkpoint (Figure 7C). Consistently, a role for FANCI in checkpoint maintenance was reported in a recent study [10].

It follows that defects in initiating the DDR, engaging HR, and maintaining the checkpoint impact cellular DNA damage resistance. Reduced DNA repair and/or checkpoint maintenance defects could explain why FA-J cells expressing the acetylation mutant FANCI^{K1249R} were sensitive to zeocin. Defects in repair and in maintaining the checkpoint may not increase cellular sensitivity if backup lesion processing mechanisms serve to process or bypass the lesion. Compensatory pathways could explain the lack of CPT-sensitivity in the FA-J cells with or without acetylation mutants (Figure S2). In support of this idea, our data reveal that FA-J cells expressing the acetylation mutant were resistant to DNA damage by relying on tolerance factors. As such, depletion of pol η in FA-J cells expressing the non-acetylatable FANCI^{K1249R} mutant reversed the UV and MMC resistance. Instead, FA-J cells expressing the acetylation mimic FANCI^{K1249Q} maintained zeocin and MMC resistance in a Rad54-dependent manner. These findings suggest that the toxicity to ICLs lesions as found in cells deficient for FANCI is avoided because FANCI enzyme active acetylation mutants facilitate recombination in S phase or translesion synthesis bypass of unhooked ICL lesions perhaps in mitosis. In the absence of a maintained checkpoint, however recombination similar to translesion synthesis bypass is likely to be error-prone.

Previously, we found that BRCA1 binding to FANCI altered FANCI function in HR and translesion synthesis pathways. Indeed, we find that similar to FA-J cells expressing the acetylation FANCI^{K1249R} mutant, FA-J cells expressing the BRCA-interaction defective mutant, FANCI^{S990A} were hyper-resistant to UV induced damage, sensitive to zeocin induced damage, and relied on pol η for MMC resistance [7]. Data also indicate that similar to FANCI^{K1249R}, the FANCI^{S990A} mutant fails to maintain the checkpoint. In response to melphalan treatment, FA-J cells expressing the FANCI^{S990A} mutant, as compared to FANCI^{WT}, underwent a reduced and more rapid G2/M checkpoint exit [7]. These similar outcomes do not reflect common defects in BRCA1 binding or acetylation. Indeed, the FANCI^{S990A} mutant was acetylated upon co-transfection of CBP to levels similar to those observed for FANCI^{WT} (data not shown). Moreover, co-precipitation experiments demonstrated that the FANCI^{K1249R} mutant






Figure 7. FANCI and its dynamic regulation by acetylation promote resection-associated events. A. Deficiency in FANCI or its acetylation impairs the CPT-induced Rad51 focus formation. The FA-J cell lines were seeded onto 6-well plates, incubated overnight, left untreated or treated with CPT 6 h and immunofluorescence was performed with the indicated antibodies. The percent of cells with γ -H2AX and Rad51 foci was quantified and graphed. Data represent mean percent \pm s.d. from three independent experiments. B. Deficiency in FANCI or its ability to be regulated by acetylation impairs the CPT-induced checkpoint response. FA-J cell lines were either left untreated or treated for 1 h with the 0.1 μ M or 1 μ M of CPT and analyzed at the indicated time points. Cell lysates were collected, lysed, and analyzed with the indicated antibodies. C. Model depicts function of FANCI acetylation in the DDR. FANCI acetylation at lysine 1249 promotes resection and HR whereas de-acetylation promotes translesion synthesis (TLS). Maintenance of the checkpoint response; however requires the dynamic regulation of FANCI acetylation. doi:10.1371/journal.pgen.1002786.g007

bound BRCA1 as well as FANCI^{WT}. Thus, BRCA1 binding and acetylation of FANCI may be distinct events. Nevertheless, defects in BRCA1 binding at serine 990 or acetylation at lysine 1249 could have similar outcomes for FANCI function because both mutants fail to maintain a robust checkpoint and Rad51-based repair is reduced [9].

A stalled replication fork with exposed single stranded and double stranded regions could provide an ideal DNA substrate for FANCI. Indeed, FANCI requires several nucleotides for binding and metabolizing DNA [20]. FANCI function in replication fork processing could also be similar to other 5'-3' DNA helicase/translocases such as *E. coli* RecD and yeast Rad3. Rad3 facilitates exonucleolytic degradation of DNA ends, which restricts recombination between short homologous sequences [21]. Interestingly, RecD regulates resection and recombination by changes in helicase speed, which can also facilitate a polymerase swap, in which bypass polymerases diminish fork break down [22]. Conceivably, enhanced FANCI enzyme activity or altered substrate preference due to acetylation could generate more single-stranded DNA to elicit checkpoint responses such as RPA loading as proposed [19]. Alternatively, checkpoint maintenance could require reduced FANCI enzyme activity so that FANCI does not displace proteins from lesions, such as RAD51 or interacting partners BRCA1, RPA and BLM helicase [6], [23–25]. In this context, it is worth noting that changes in motor speed have been associated with FANCI clinical mutants. The breast cancer associated mutant, M299I is enzyme activating and both unwinds and translocates DNA more efficiently than FANCI^{WT}, whereas the P47A mutant is enzyme inactivating [26], [27]. Whether changes in FANCI function derive from acetylation and/or partners that bind via this modification remains to be determined. Furthermore, based on our current data, it is unclear if distinct DNA lesions selectively induce FANCI acetylation.

In summary, our findings indicate that FANCI has the ability to potentiate HR through dual roles in DNA end processing and checkpoint maintenance. These two functions require FANCI lysine 1249, a site not conserved in FANCI orthologues such as chicken FANCI and *C. elegans* Dog-1. Interestingly, unlike in human cells, FANCI does not function in HR in chicken and *C. elegans* systems [28], [29]. It is not surprising that regulators of FANCI acetylation state, HDACIII, SIRT1, and CBP have roles in DNA repair and genomic stability [30–32]. It remains to be determined, however, whether associated repair defects are related to failure to regulate FANCI acetylation. Complicating this analysis, HDACIII, SIRT1, and CBP have many other histone and non-histone protein substrates that also have role in DNA repair and genomic stability. For example, SIRT1 deacetylation plays an important role in regulating the function of DNA double strand break repair proteins, such as Ku70 [33], WRN [34], and NBS1 [35]. Moreover, p300/CBP functions to regulate the activities of multiple proteins at the replication fork including PCNA [36]. CBP also regulates the activity of other helicases, including WRN [37]. Whether HDAC or HAT associated defects derive from a failure to regulate FANCI acetylation will be an important question for future studies.

Materials and Methods

Cell lines

MCF7, HeLa, and 293T cells were grown in DMEM supplemented with 10% fetal bovine serum and penicillin/streptomycin (100 U/mL each). FA-J (EUFA30-F) cells were cultured with 15% fetal bovine serum and penicillin/streptomycin (100 U/mL each). FA-J cells were infected with the POZ retroviral vector [38] containing no insert, WT, K1249R, or K1249Q FANCI inserts. Stable FA-J POZ cell lines were selected as before [8].

Immunoprecipitation and Western blot assays

Cells were harvested, lysed, and processed for Western blot analysis as described previously using an NETN lysis buffer (20 mM Tris, 150 mM NaCl, 1 mM EDTA, and 0.5% NP-40) containing 10 mM NaF and 1 mM NaVO₃ [7]. For acetylation detection, unless otherwise noted cells were lysed with 150 mM NETN buffer supplemented with 10 μ M TSA and 5 mM nicotinamide. For γ -H2AX detection, cell pellets were collected and dissolved and boiled in 2 \times lysis buffer (50 mM Tris pH 6.8, 2% SDS, 1% B-ME). Antibodies used for immunoprecipitation (IP) and Western blot assays include FANCI polyclonal Abs E67 [26], β -Actin (Sigma), pRPA S3/4 (Bethyl), RPA (Bethyl), pChk1 S317 (Bethyl), Chk1 (Bethyl), pChk2 (Cell signaling), Chk2 (Cell Signaling), γ -H2AX S139 (Millipore), H2AX (Bethyl), Flag (Sigma), HA (12C4), pan-acetylated lysine (Cell signaling), MLH1 (BD Bioscience), BRCA1 monoclonal (ms110), pH 3 (Millipore), H3 (Abcam), pol η (Abcam), Rad54 (Abcam), Rad51 (Abcam), and Myc monoclonal (9E10).

Cell cycle progression assay

FA-J stable cell lines were either mock treated or treated with 0.25 μ g/ml of melphalan (Sigma) and incubated for various times. Cells were fixed with 90% methanol in PBS overnight and then incubated 10 min with PBS containing 30 μ g/ml DNase-free RNase A and 50 μ g/ml propidium iodide. 1×10^4 cells were analyzed using a FACs Calibur instrument (Becton-Dickinson, San Jose, CA). Aggregates were gated out and the percentage of cells in G2/M was calculated using Flow Jo software.

Plasmid construction

The pCDNA3-myc.his vector (Invitrogen) was digested by NotI/ApaI and different FANCI fragments generated by PCR and digested by NotI/ApaI were inserted. Primers are available upon request. Reverse primers used for K1249R-pCDNA3 and K1249RQ-pCDNA3 are 5'TTTTGGGCCCTAAAACCAG-GAAACATGCC3' and 5'TTTTGGGCCCTGAAAACCAG-GAAACATGCC3', respectively. The K1249R and K1249Q pOZ vectors were generated with the QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) by using the FANCI-pCDNA3-myc.his or FANCI-pOZ as a template and the following primers: (K1249R-pOZ-Forward) 5'GGCATGTTTCCTGGT-TTTAGGGCGCCGCTGGAGAGCA3' and (K1249R-

pOZ-Reverse) 5'GTCTCCTCCAGCGGCCGCCCTAAAAC-CAGGAAACATGCC3'; (K1239Q-pOZ-Forward) 5'GGCATGTTTCTGTTTTCAGGCGGCCGCTGGAGGAGAC3' and (K1239Q-pOZ-Reverse) 5'GTCTCCTCCAGCGGCCGCCCTGAAAACAGGAAACATGCC3'; Recombinant FANCI protein production was made in insect cells using the PVL13.2 vector as before [26]. Full-length WT *FANCI* was used as a template to generate the acetylation mutants using the following primers: (K1249R-PVL132 Forward) 5'GGCATGTTTCTGTTTTCAGGCGGCCGCTGGAGGAGAC3' and (K1249-PVL132 Reverse) 5'CGTCGTCCTTGTAGTCCCTAAAACAGGAAACATGCC3'. (K1249Q-PVL132 Forward) 5'GGCATGTTTCTGTTTTCAGGCGGCCGCTGGAGGAGAC3' and (K1249Q-PVL132 Reverse) 5'CGTCGTCCTTGTAGTCCCTAAAACAGGAAACATGCC3'. The pGEX-5X vector (GE Healthcare Life Sciences) was digested by *Sall*/*NotI* and the FANCI C-terminal fragment was generated by PCR and digested by *Sall*/*NotI* and inserted. Primers are available upon request. All DNA constructs were confirmed by DNA sequencing.

Viability assays

Stable FA-J cell lines were untransfected or transfected with siRNA previously described against *Luc*, *Rad54*, or *polη* [9]. Cells were seeded onto 6 well plates and incubated overnight. Seeded cells were either untreated or treated with increasing dose of MMC (1 h, serum free), UV, CPT, (1 h, serum free), or zeocin (1 h, serum free). To assay for percent survival, cells were counted 5–8 days post infection and percent survival was calculated as before [9].

Helicase assays

Helicase assay reaction mixtures (20 μ l) contained 40 mM Tris-HCl (pH 7.4), 25 mM KCl, 5 mM MgCl₂, 2 mM dithiothreitol, 2% glycerol, 100 ng of bovine serum albumin/ μ l, 2 mM ATP, 10 fmol of 19-bp duplex DNA substrate (0.5 nM), and the concentrations of FANCI (acetylated or non acetylated) indicated in the figures. Helicase reactions were initiated by the addition of FANCI, and the reaction mixtures were incubated at 30°C for 15 min unless otherwise indicated. Reactions were quenched with the addition of 20 μ l of 2 \times Stop buffer (17.5 mM EDTA, 0.3% SDS, 12.5% glycerol, 0.02% bromophenol blue, 0.02% xylene cyanol). For standard duplex DNA substrates, a 10-fold excess of unlabeled oligonucleotide with the same sequence as the labeled strand was included in the quench to prevent reannealing. Reaction products were resolved on nondenaturing 12% (19:1 acrylamide-bisacrylamide) polyacrylamide gels, and quantitated as described previously [27].

Immunofluorescence microscopy

Stable FA-J cell lines were seeded onto 6 well plates and incubated overnight. Cells were either untreated or treated with 1 mM HU (24 h) or 0.25 μ M CPT (1 h). Cells were fixed with 3% paraformaldehyde/2% sucrose for 10 min at RT, and permeabilized with 0.5% Triton X-100 in 20 mM HEPES for 5 min on ice. Incubation with antibodies and washes were described previously [6]. For *Rad51* staining, cells were fixed with 3% paraformaldehyde/2% sucrose for 10 min at RT, permeabilized with ice-cold methanol for 30 min, and blocked with 4% BSA for 1 h. Staining was as described previously [6].

In vitro acetylation assay

The acetyltransferase assays were performed in 30 μ l of reaction, which includes reaction buffer (50 mM HEPES

(pH 8.0), 10% glycerol, 1 mM DTT, 1 mM PMSF, 10 mM Na-butyrate), 1 μ l [³H]-acetyl-CoA, 1 μ l recombinant HAT domain of p300 (gift of Dr. Luo), and recombination FANCI-CT or p53-CT [39]. Reaction were carried out at 30°C for 1 h and separated by SDS-PAGE, analyzed by autoradiography. Concentrations of recombinant proteins were determined by comassie staining from Invitrogen.

In gel digestion

Gel bands containing FANCI1 were de-stained twice with 25 mM ammonium bicarbonate in 50% acetonitrile for 30 min in 37°C, reduced with 7.6 mg/ml dithiothreitol at 60°C for 10 min, and alkylated with 18.6 mg/mL iodoacetamide at room temperature for 1 hour. The bands were then washed twice with 25 mM ammonium bicarbonate in 50% acetonitrile for 15 min at 37°C prior to shrinking with 50 μ l acetonitrile for 10 min at room temperature. 100 ng trypsin (Promega) was added to each sample and 25 mM ammonium bicarbonate was added until the gels were fully swollen (~10–50 μ l) and the digestion proceeded overnight at 30°C. Following digestion, peptide extracts were transferred into new tubes and the gels were further extracted with 50 μ l of 50% acetonitrile containing 5% formic acid (v/v) and following 15 min were added to the initial extracts. The latter process was repeated for a total of three extractions. Extracts were then dried on a SpeedVac and reconstituted in 20 μ l of 0.1% formic acid for LC-MS/MS analysis.

LC/MS/MS

Tryptic peptides (2 μ l) were directly loaded at 4 μ l/min for 7 min onto a custom-made trap column (100 μ m I.D. fused silica with Kasil frit) containing 2 cm of 200 Å , 5 μ m Magic C18AQ particles (Michrom Bioresources). Peptides were then eluted using a custom-made analytical column (75 μ m I.D. fused silica) with gravity-pulled tip and packed with 25 cm 100 Å , 5 μ m Magic C18AQ particles (Michrom). Peptides were eluted with a linear gradient from 100% solvent A (0.1% formic acid:acetonitrile (95:05)) to 35% solvent B (acetonitrile containing 0.1% formic acid) in 35 min at 300 nL/min using a Proxeon Easy nanoLC system directly coupled to a LTQ Orbitrap Velos mass spectrometer (Thermo Scientific) [40]. Data were acquired using a data-dependent acquisition routine of acquiring one mass spectrum from *m/z* 350–2000 in the Orbitrap (resolution 60,000) followed by tandem mass spectrometry scans in the LTQ linear ion trap of the 10 most abundant precursor ions found in the mass spectrum. Charge state rejection of singly-charged ions and dynamic exclusion was utilized to minimize data redundancy and maximize peptide identification [41].

Data analysis

The raw data files were processed and searched against the human index of the SwissProt database (version 09/21/11) containing both the mutant and wild-type forms of FANCI1 with Mascot (version 2.3.02; Matrix Science) using parent mass tolerances of 15 ppm and fragment mass tolerances of 0.5 Da. Full tryptic specificity with 2 missed cleavages was used and variable modifications of acetylation (protein N-term and lysine), pyro-glutamination (N-term glutamine), and oxidation (methionine), and fixed modification of carbamidomethylation (cysteine) were considered. Mascot search results were also loaded into Scaffold (Version 3.3.1; Proteome Software) for comparative analyses using spectral counting of tandem mass spectra and full annotation of the data [42].

Supporting Information

Figure S1 FANCI acetylation sites. Identified acetylation sites of FANCI protein by mass spectrometry (bold): acetylated peptides unique to WT (red); unique to K1249R mutant (green); and common to both (black). (EPS)

Figure S2 FA-J cells expressing FANCI acetylation mutants have a distinct response to UV and zeocin induced damage. The FA-J cell lines were either untreated or treated with increasing doses of UV, zeocin, or CPT and allowed to grow for 8 days. Cells were counted and percent survival was calculated. Data represent mean percent \pm s.d. of survival from three independent experiments. (EPS)

Figure S3 FANCI^{WT}, FANCI^{K1249R}, and FANCI^{K1249Q} have similar catalytic activities. FANCI^{WT}, FANCI^{K1249R}, and FANCI^{K1249Q} recombinant proteins were incubated with forked duplex substrate at 30°C for 15 min. Reaction products were analyzed by nondenaturing gel electrophoresis. Data represent mean percent \pm s.d. of growth from three independent experiments. (EPS)

References

- Sobhan B, Shao G, Lilli DR, Culhane AC, Moreau LA, et al. (2007) RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. *Science* 316: 1198–1202.
- Wang B, Matsuoka S, Ballif BA, Zhang D, Smogorzewska A, et al. (2007) Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. *Science* 316: 1194–1198.
- Sartori AA, Lukas C, Coates J, Mistrik M, Fu S, et al. (2007) Human CtIP promotes DNA end resection. *Nature* 450: 509–514.
- Cantor SB, Guillemette S (2011) Hereditary breast cancer and the BRCA1-associated FANCI/BACH1/BRIP1. *Future oncology* 7: 253–261.
- Wu Y, Suhasini AN, Brosh RM, Jr. (2009) Welcome the family of FANCI-like helicases to the block of genome stability maintenance proteins. *Cell Mol Life Sci* 66: 1209–1222.
- Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, et al. (2001) BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. *Cell* 105: 149–160.
- Litman R, Peng M, Jin Z, Zhang F, Zhang J, et al. (2005) BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCI. *Cancer Cell* 8: 255–265.
- Peng M, Litman R, Xie J, Sharma S, Brosh RM, Jr., et al. (2007) The FANCI/MutLalpha interaction is required for correction of the cross-link response in FA-J cells. *Embo J* 26: 3238–3249.
- Xie J, Litman R, Wang S, Peng M, Guillemette S, et al. (2010) Targeting the FANCI-BRCA1 interaction promotes a switch from recombination to poleta-dependent bypass. *Oncogene* 29: 2499–2508.
- Cotta-Ramusino C, McDonald ER, 3rd, Hurov K, Sowa ME, Harper JW, et al. (2011) A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1 interacting protein required for ATR signaling. *Science* 332: 1313–1317.
- Peng M, Litman R, Jin Z, Fong G, Cantor SB (2006) BACH1 is a DNA repair protein supporting BRCA1 damage response. *Oncogene* 25: 2245–2253.
- Levitus M, Waisfisz Q, Godthelp BC, de Vries Y, Hussain S, et al. (2005) The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. *Nat Genet* 37: 934–935.
- Levran O, Attwooll C, Henry RT, Milton KL, Neveling K, et al. (2005) The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. *Nat Genet* 37: 931–933.
- Wu Y, Brosh RM, Jr. (2009) FANCI helicase operates in the Fanconi Anemia DNA repair pathway and the response to replicational stress. *Curr Mol Med* 9: 470–482.
- Yu X, Wu LC, Bowcock AM, Aronheim A, Baer R (1998) The C-terminal (BRC1) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. *J Biol Chem* 273: 25388–25392.
- Kaidi A, Weinert BT, Choudhary C, Jackson SP (2010) Human SIRT6 promotes DNA end resection through CtIP deacetylation. *Science* 329: 1348–1353.
- Marks PA, Miller T, Richon VM (2003) Histone deacetylases. *Curr Opin Pharmacol* 3: 344–351.
- Zhan Q, Jin S, Ng B, Plisket J, Shangary S, et al. (2002) Caspase-3 mediated cleavage of BRCA1 during UV-induced apoptosis. *Oncogene* 21: 5335–5345.
- Gong Z, Kim JE, Leung CC, Glover JN, Chen J (2010) BACH1/FANCI acts with TopBP1 and participates early in DNA replication checkpoint control. *Molecular cell* 37: 438–446.
- Gupta R, Sharma S, Doherty KM, Sommers JA, Cantor SB, et al. (2006) Inhibition of BACH1 (FANCI) helicase by backbone discontinuity is overcome by increased motor ATPase or length of loading strand. *Nucleic Acids Res* 34: 6673–6683.
- Bailis AM, Maines S, Negritto MT (1995) The essential helicase gene RAD3 suppresses short-sequence recombination in *Saccharomyces cerevisiae*. *Mol Cell Biol* 15: 3998–4008.
- Dillingham MS, Kowalczykowski SC (2008) RecBCD enzyme and the repair of double-stranded DNA breaks. *Microbiol Mol Biol Rev* 72: 642–671, Table of Contents.
- Sommers JA, Rawtani N, Gupta R, Bugreev DV, Mazin AV, et al. (2009) FANCI uses its motor ATPase to disrupt protein-DNA complexes, unwind triplexes, and inhibit rad51 strand exchange. *J Biol Chem*.
- Gupta R, Sharma S, Sommers JA, Kenny MK, Cantor SB, et al. (2007) FANCI (BACH1) helicase forms DNA damage inducible foci with replication protein A and interacts physically and functionally with the single-stranded DNA-binding protein. *Blood* 110: 2390–2398.
- Suhasini AN, Rawtani NA, Wu Y, Sommers JA, Sharma S, et al. (2011) Interaction between the helicases genetically linked to Fanconi anemia group J and Bloom's syndrome. *The EMBO journal* 30: 692–705.
- Cantor S, Drapkin R, Zhang F, Lin Y, Han J, et al. (2004) The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. *Proc Natl Acad Sci U S A* 101: 2357–2362.
- Gupta R, Sharma S, Sommers JA, Jin Z, Cantor SB, et al. (2005) Analysis of the DNA substrate specificity of the human BACH1 helicase associated with breast cancer. *J Biol Chem* 280: 25450–25460.
- Bridge WL, Vandenberg CJ, Franklin RJ, Hiom K (2005) The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair. *Nat Genet* 37: 953–957.
- Youds JL, Barber IJ, Ward JD, Collis SJ, O'Neil NJ, et al. (2008) DOG-1 is the *Caenorhabditis elegans* BRIP1/FANCI homologue and functions in interstrand cross-link repair. *Mol Cell Biol* 28: 1470–1479.
- Bhaskara S, Hiebert SW (2011) Role for histone deacetylase 3 in maintenance of genome stability. *Cell Cycle* 10: 727–728.
- Haigis MC, Sinclair DA (2010) Mammalian sirtuins: biological insights and disease relevance. *Annu Rev Pathol* 5: 253–295.
- Iyer NG, Ozdag H, Caldas C (2004) p300/CBP and cancer. *Oncogene* 23: 4225–4231.
- Jeong J, Juhn K, Lee H, Kim SH, Min BH, et al. (2007) SIRT1 promotes DNA repair activity and deacetylation of Ku70. *Exp Mol Med* 39: 8–13.
- Li K, Casta A, Wang R, Lozada E, Fan W, et al. (2008) Regulation of WRN protein cellular localization and enzymatic activities by SIRT1-mediated deacetylation. *J Biol Chem* 283: 7590–7598.
- Yuan Z, Zhang X, Sengupta N, Lane WS, Seto E (2007) SIRT1 regulates the function of the Nijmegen breakage syndrome protein. *Mol Cell* 27: 149–162.

Figure S4 FANCI is required for promoting CPT induced RPA phosphorylation. U2OS cells stably expressing shLuc or shFANCI were either untreated or treated with CPT. Cell lysates were collected and analyzed with the indicated antibodies. (EPS)

Figure S5 FANCI is not required for promoting zeocin induced RPA phosphorylation. The FA-J cell lines were either untreated or treated with the denoted dose of zeocin. Cell lysates were collected and analyzed with the indicated antibodies. (JPG)

Acknowledgments

We thank Dr. Jianyuan Luo (University of Maryland) for helpful discussions and acetylation reagents.

Author Contributions

Conceived and designed the experiments: SBC RMB SAS. Performed the experiments: JX MP SG AV YW SQ SM. Analyzed the data: SBC RMB SAS. Contributed reagents/materials/analysis tools: SBC RMB SAS. Wrote the paper: SBC.

36. Naryzhny SN, Lee H (2004) The post-translational modifications of proliferating cell nuclear antigen: acetylation, not phosphorylation, plays an important role in the regulation of its function. *J Biol Chem* 279: 20194–20199.
37. Li K, Wang R, Lozada E, Fan W, Orren DK, et al. (2010) Acetylation of WRN protein regulates its stability by inhibiting ubiquitination. *PLoS One* 5: e10341. doi:10.1371/journal.pone.0010341
38. Nakatani Y, Ogryzko V (2003) Immunoaffinity purification of mammalian protein complexes. *Methods Enzymol* 370: 430–444.
39. Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. *Cell* 90: 595–606.
40. Olsen JV, Schwartz JC, Griep-Raming J, Nielsen ML, Damoc E, et al. (2009) A dual pressure linear ion trap Orbitrap instrument with very high sequencing speed. *Molecular & cellular proteomics : MCP* 8: 2759–2769.
41. Second TP, Blethrow JD, Schwartz JC, Merrihew GE, MacCoss MJ, et al. (2009) Dual-pressure linear ion trap mass spectrometer improving the analysis of complex protein mixtures. *Analytical chemistry* 81: 7757–7765.
42. Searle BC (2010) Scaffold: a bioinformatic tool for validating MS/MS-based proteomic studies. *Proteomics* 10: 1265–1269.